RT Journal Article
SR Electronic
T1 Viral load of SARS-CoV-2 Omicron BA.5 is lower than that of BA.2 despite the higher infectivity of BA.5
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.25.22281427
DO 10.1101/2022.10.25.22281427
A1 Takatsuki, Yuna
A1 Takahashi, Yuta
A1 Nakajima, Jun
A1 Iwasaki, Yumi
A1 Nagano, Katsutoshi
A1 Tani-Sassa, Chihiro
A1 Yuasa, Sonoka
A1 Kanehira, Saki
A1 Sonobe, Kazunari
A1 Nukui, Yoko
A1 Takeuchi, Hiroaki
A1 Tanimoto, Kousuke
A1 Tanaka, Yukie
A1 Kimura, Akinori
A1 Ichimura, Naoya
A1 Tohda, Shuji
YR 2022
UL http://medrxiv.org/content/early/2022/10/28/2022.10.25.22281427.abstract
AB Sublineage BA.5 of the SARS-CoV-2 Omicron variant rapidly spread and replaced BA.2 in July 2022 in Tokyo. A high viral load can be a possible cause of high transmissibility. Therefore, the copy numbers of SARS-CoV-2 in nasopharyngeal swab samples obtained from all patients visiting the hospital where this research was conducted were measured using quantitative polymerase chain reaction (qPCR). Viral genotypes were determined using PCR-based melting curve analysis. Next, whole-genome sequencing was performed using approximately one-fifth of the samples to verify the viral genotypes determined using PCR. Then, the copy numbers of the BA.1, BA.2, and BA.5 cases were compared. Contrary to expectations, the copy numbers of the BA.5 cases (median 4.7 × 104 copies/μL, n = 290) were significantly (p = 0.001) lower than those of BA.2 cases (median 1.1 × 105 copies/μL, n = 184). There was no significant difference between the BA.5 and BA.1 cases (median, 3.1 × 104 copies/μL; n = 215). The results presented here suggest that the increased infectivity of BA.5 is not caused by higher viral loads, but presumably by other factors such as increased affinity to human cell receptors or immune escape due to its L452R mutation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the grant JPMJCR20H2 from JST-CREST and 20nk0101612h0901 from the Japan Agency for Medical Research and Development.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Medical Research Ethics Committee of Tokyo Medical and Dental University gave ethical approval for this work (approval number: M2020-004).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors